20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T4694 | AG-1557 hydrochloride (189290-58-2(free base)) | EGFR , HER | |
AG-1557 hydrochloride is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (pIC50: 8.194). | |||
T6266 | PP2 | AGL 1879,AG 1879,AGL 1879 | EGFR , Tyrosine Kinases , JAK , Src |
PP2 (AG 1879,AGL 1879) is a effective inhibitor of Lck/Fyn (IC50:4/5 nM) , ~100-fold less potent to EGFR, inactive for ZAP-70, PKA and JAK2. | |||
T7493 | AG-13958 | AG-013958 | VEGFR |
AG-13958 (AG-013958) (AG-013958), a potent VEGFR tyrosine kinase inhibitor, for the treatment of age-related macular degeneration. | |||
T1088 | Repaglinide | AG-EE 388 ZW,AG-EE 623ZW | Potassium Channel , PPAR |
Repaglinide (AG-EE 623ZW) is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Repaglinide has been linked to rare instances of clinically appare... | |||
T13238 | Tyrphostin AG1433 | SU1433,AG1433 | VEGFR , PDGFR |
Tyrphostin AG1433 (AG1433) is an inhibitor of tyrosine kinases and also a dual inhibitor of PDGFRβ(IC50s = 5.0 μM) and VEGFR-2 (Flk-1/KDR)(IC50s = 9.3 μM). | |||
T22253 | AG-120 (racemic) | Dehydrogenase | |
AG-120 (racemic), the racemic mixture of AG-120, is an orally available isocitrate dehydrogenase type 1 (IDH1) inhibitor, and shows potential antineoplastic activity. | |||
T4052 | KML29 | Lipase | |
KML29 is highly selective and effective monoacylglycerol lipase (MAGL) inhibitor. It has effective inhibition of human/mouse/rat MAGL (IC50: 5.9/15/43 nM). It has not inhibitory for FAAH (IC50 > 50 μM). It also effective... | |||
T29372 | 2-Pyridineacetamide, 5-ethylthio- | AG-41,AG 41,AG41 | |
2-Pyridineacetamide, 5-ethylthio- is a biochemical. | |||
T29373 | 2-Pyridineacetamide, 5-methylthio- | AG 42,AG-42 AG42 | |
2-Pyridineacetamide, 5-methylthio- is a biochemical. | |||
T22456 | Voreloxin hydrochloride | SNS-595 hydrochloride,Vosaroxin | Apoptosis , Topoisomerase |
Voreloxin hydrochloride (SNS-595 hydrochloride) is a potent inhibitor of Topoisomerase II with broad-spectrum anti-tumor activity. | |||
T4554 | AG 1406 | VEGFR | |
AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2. | |||
T2346 | Enasidenib | AG-221 | Dehydrogenase , Isocitrate Dehydrogenase (IDH) |
Enasidenib (AG-221) is an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. | |||
T11724 | JNJ-42226314 | Lipase | |
JNJ-42226314 is a highly selective non-covalent monoacylglycerol lipase (MAGL) inhibitor with anti-injury effects.JNJ-42226314 shows efficacy via endogenous cannabinoid-2-acryloylglycerol (2-AG) in models of neuropathic ... | |||
T14137 | AG 1295 | PDGFR | |
AG 1295, a selective inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine-kinase, effectively halts PDGFR autophosphorylation without impacting the autophosphorylation of the EGF receptor[1][2][3][4]. | |||
T4205 | AG-494 | Tyrphostin AG-494,AG 494,Tyrphostin B48 | EGFR , CDK |
AG-494 (Tyrphostin B48) is an inhibitor of epidermal growth factor receptor kinase. | |||
T1452 | Axitinib | AG-013736 | VEGFR , PDGFR , c-Kit |
Axitinib (AG-013736) is an orally bioavailable tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.7, 1.6 nM for VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFRβ, respectively. | |||
T3617 | Ivosidenib | AG-120 | Dehydrogenase , Isocitrate Dehydrogenase (IDH) |
Ivosidenib (AG-120) is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhi... | |||
T4092 | AG126 | Tyrphostin AG126,AG 126 | ERK , COX |
AG126 (Tyrphostin AG126) selectively inhibits the phosphorylation of ERK1 (p44) and ERK2 (p42) at 25-50 μM. It blocks the production of TNF-α in vitro2 and in vivo, attenuating signaling through NF-κB, the induced expres... | |||
T6554 | JZL 184 | JZL184 | Lipase |
JZL 184 is a potent and selective inhibitor of MAGL with IC50 of 8 nM and 4 μM for inhibition of MAGL and FAAH in mouse brain membranes respectively. | |||
T5815 | MJN110 | Cravatt Reagent | Lipase |
MJN110 (Cravatt Reagent) is a potent and selective MAGL inhibitor. Cravatt Reagent inhibits MAGL (IC50 = 9.1 nM). MJN110(Cravatt Reagent) Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. |